Cryptocurrencies: 3,850
Markets: 22,658
ICO's: 4,983
Market Cap: $274,716,884,752
24h Vol: $67,861,639,092
Dominance: 64.7%
 Vivo Capital

Vivo Capital

Future of Healthcare Innovation

Website

Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China. With more than $1.7 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Shanghai, and Beijing, China. At Vivo Capital, we leverage our internal expertise in evaluating data to generate outsized returns for company founders and employees as well as for our investors. Vivo invests primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China. Vivo assists its portfolio companies in both countries in forging cross-border partnerships, enabling the companies to acquire new products and expand the market for their existing products. In addition to making investments in existing companies, Vivo also builds companies from scratch to pursue compelling opportunities together with experienced management teams. Finally, a portion of every Vivo fund is invested directly into public therapeutics companies. Despite its focus on companies with later-stage products, Vivo is willing to work with companies (and their founders) that may not have significant infrastructure. We invest in companies with promising products at all financing stages (Series A to public companies), and work closely with founders and management to complete the development and commercial launch of those products and achieve a successful exit.


About Vivo Capital

Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies in the U.S. and China. With more than $1.7 billion under management, Vivo employs a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in China. Vivo Capital has offices in Palo Alto, California, Shanghai, and Beijing, China.

At Vivo Capital, we leverage our internal expertise in evaluating data to generate outsized returns for company founders and employees as well as for our investors. Vivo invests primarily in later development stage pharmaceutical and medical device companies in the U.S. and in revenue stage healthcare companies in greater China. Vivo assists its portfolio companies in both countries in forging cross-border partnerships, enabling the companies to acquire new products and expand the market for their existing products. In addition to making investments in existing companies, Vivo also builds companies from scratch to pursue compelling opportunities together with experienced management teams. Finally, a portion of every Vivo fund is invested directly into public therapeutics companies. Despite its focus on companies with later-stage products, Vivo is willing to work with companies (and their founders) that may not have significant infrastructure. We invest in companies with promising products at all financing stages (Series A to public companies), and work closely with founders and management to complete the development and commercial launch of those products and achieve a successful exit.

The Team

Lawrence Wang

Managing Director

Michael Chang

Managing Director

Jack Bech Nielsen

Managing Director

Gaurav Aggarwal

Managing Director

Frank Kung

Managing Partner

Albert Cha

Managing Partner

Shan Fu

Managing Partner

Chen Yu

Managing Partner

Derek Yang

Finance Director

Peiyi Zhao

Head of Legal

Albert Chang

Managing Partner

Edgar G. Engleman

Managing Partner

Mahendra G. Shah

Managing Director

Hwachie Lee

Managing Director

Jo Shen

Venture Partner

Yuh-geng Tsay

Venture Partner

Tracy Wu

General Director

Joseph Siletto

Managing Director

Daisy Xu

General Director

Nathan Dau

Associate

Eric Trac

Associate

Tiantian Zhu

Analyst

Ethan Zhao

Associate

Tierney Y. Li

Analyst

Andrew D. Goldberg

Principal

Vinayak Nikam

Associate

Adrianne Chang

Consultant

Dan Dan Dong

Principal

Qi Zhu

Principal

Nina Feng

Principal

Kevin Dai

Principal

David Liu

Principal

Daniel Qin

Associate

Lingfei Zhao

Analyst

Sue Shao

Associate

Yixuan Li

Analyst

Waika Cheng

Analyst

Aaron Royston

Senior Associate

Ronghuan Lin

Advisor

Financials

Token Info

Type
ERC20
Price in ICO
1 VCT = 0.00002 ETH

Investment Info

Min. investment
0.1 ETH

Related ICOs

Name Status Start Date End Date Total Supply Category Listing
Geco.one
Active
Dec 24th Dec 25th 550,000,000 Platform
Basic